Alan David Woolf, M.D.
|Title||Professor of Pediatrics|
|Institution||Children's Hospital Boston|
1295 Boylston St, 1st floor
Boston MA 02115
Available: 10/02/13, Expires: 12/31/13
Use of the intravenous chelant, CaNa2EDTA, is an important aspect of the management of the hospitalized child with moderate-severe lead poisoning. This drug is problem prone and errors in dose calculation, the drug's intravenous administration, and the subsequent monitoring of the patient are common. In this project, we describe a 'critical pathway' developed by clinicians and pharmacists at Boston Children's Hospital in 2005 for the safe delivery of CaNa2EDTA to a pediatric patient. We will compare aspects of the hospital course for those pediatric patients who were treated prior to institution of the critical pathway (1990-2004) to those treated after the guidance was issued for pharmacy, nursing, and medical staff (2005-2013). The goals of the study are to determine if the critical pathway has made a difference in the quality of care delivered to the hospitalized child, whether it made a difference in the frequency of errors in dosing or administration, or changes in the baseline and follow-up laboratory monitoring of the patient's condition.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.